11,555 Shares in Disc Medicine, Inc. $IRON Purchased by Jupiter Topco LLC

Jupiter Topco LLC bought a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,555 shares of the company’s stock, valued at approximately $844,000. Jupiter Topco LLC owned approximately 0.30% of Disc Medicine as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in shares of Disc Medicine in the 2nd quarter worth approximately $1,350,000. The Manufacturers Life Insurance Company purchased a new position in Disc Medicine in the 2nd quarter worth approximately $2,031,000. Algert Global LLC lifted its position in Disc Medicine by 128.6% in the 2nd quarter. Algert Global LLC now owns 51,850 shares of the company’s stock valued at $3,792,000 after acquiring an additional 29,170 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Disc Medicine in the second quarter worth $153,000. Finally, Allworth Financial LP bought a new position in shares of Disc Medicine during the second quarter valued at $46,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IRON shares. Morgan Stanley reissued an “overweight” rating and set a $90.00 price objective on shares of Disc Medicine in a report on Monday, August 17th. Wedbush increased their price target on Disc Medicine from $88.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, September 2nd. HC Wainwright lifted their price objective on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Finally, Wall Street Zen lowered shares of Disc Medicine from a “hold” rating to a “sell” rating in a research report on Saturday, August 29th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and a consensus target price of $107.70.

Insider Activity

In related news, CEO John Quisel sold 33,000 shares of Disc Medicine stock in a transaction on Monday, August 17th. The shares were sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the transaction, the chief executive officer owned 226,064 shares in the company, valued at approximately $17,892,965.60. The trade was a 12.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rahul Khara sold 5,000 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the sale, the insider owned 52,324 shares of the company’s stock, valued at $4,185,920. This represents a 8.72% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 208,108 shares of company stock valued at $15,799,739. 3.76% of the stock is currently owned by company insiders.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $79.23 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The stock has a 50-day simple moving average of $77.76 and a two-hundred day simple moving average of $70.48. The firm has a market capitalization of $303.45 million, a PE ratio of -12.04 and a beta of 0.97. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. Analysts forecast that Disc Medicine, Inc. will post -6.61 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.